Is the Latinib the Best Choice in Patients With Brain Mats?

The median PFS of latinib were 36 months and they are at three years of follow-up. With the exception of a unique brain mats which is very rare in health brain metastatic patients we see front-end latinib. I would rather favor like Justin and probably Ben who is a very moderate today to be very transparent in the way being the main investigator of crown but I would say I would probably favor latinib for two or two reasons.